# Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

> **NCT04768699** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Hemophilia A With Inhibitor
- Hemophilia B With Inhibitor

## Interventions

- **DRUG:** TQG203
- **DRUG:** TQG203/NovoSeven®
- **DRUG:** TQG203

## Key facts

- **NCT ID:** NCT04768699
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768699, "Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04768699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*